D46 Category · further specificity required Myelodysplastic syndromes

ICD-10-CM D46 identifies “Myelodysplastic syndromes” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.

Chapter 2: Neoplasms

Code-level instructions

Excludes 21

drug-induced aplastic anemia (D61.1)

Use additional code1

code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)

Inherited instructions

Chapters 2 · Neoplasms (C00-D49)

Note8
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

D37-D48 · Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)

Excludes 11

neoplasms of unspecified behavior (D49.-)

Note1

Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.

More specific codes

Official index references
References from other codes (5)
D75.81 · Myelofibrosis

Use additional code · code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)

History

Code history

No recorded change since first observation

ChangedUnchanged
FY2016

Effective from

  • First observed

Myelodysplastic syndromes

Category — select a more specific code

CDC/NCHS · FY2016

All editions (19)

All editionsEffective fromCode history
FY20162015-10-01First observed
FY20172016-10-01No tabular change
FY20182017-10-01No tabular change
FY20192018-10-01No tabular change
FY20202019-10-01No tabular change
FY2020 · April2020-04-01No tabular change
FY20212020-10-01No tabular change
FY2021 · 01-012021-01-01No tabular change
FY20222021-10-01No tabular change
FY2022 · 04-012022-04-01No tabular change
FY20232022-10-01No tabular change
FY2023 · 04-012023-04-01No tabular change
FY20242023-10-01No tabular change
FY2024 · 04-012024-04-01No tabular change
FY20252024-10-01No tabular change
FY2025 · 04-012025-04-01No tabular change
FY20262025-10-01No tabular change
FY2026 · April2026-04-01No tabular change
FY20272026-10-01No tabular change

Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.